[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"subcutaneous\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:subcutaneous":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100641127",false,"NCT07655804","Subcutaneous Calcitonin in Acute Herpes Zoster","The Prophylactic Value of Subcutaneous Calcitonin in Acute Herpes Zoster Patients: A Randomized Controlled Trial","Inclusion Criteria:\n\n* patients aged ≥ 50 years, with acute herpes zoster infection (rash duration \\\u003C 7 days) and moderate to severe pain.\n\nExclusion Criteria:\n\n* Coagulation abnormalities\n* Pre-existing other pain syndrome or psychological disorders.\n* Severe hepatic, cardiovascular, or renal disorders.\n* Allergy to calcitonin.","ALL","50 Years",{"count":18,"type":19},168,"ESTIMATED","INTERVENTIONAL",[22],"PHASE3","This prospective randomized controlled study will be conducted to evaluate the effect of adding calcitonin to the standard treatment protocol in patients with acute herpes zoster infection.",[25,26,27],"Calcitonin","Subcutaneous","Acute Herpes Zoster","NOT_YET_RECRUITING","2026-06-13",{"date":31,"type":32},"2026-06-18","ACTUAL",{"date":34,"type":19},"2026-07-01",{"date":36,"type":19},"2027-10-01",{"name":38,"class":39},"Tanta University","OTHER",""]